Dharmisha Chauhan
@dharmisha.bsky.social
Consultant Pharmacist - Genomic Medicine at North Thames Genomic Medicine Service Alliance and Specialist Oncology Pharmacist - Lung Cancer at Royal Marsden Hospital
Pharmacogenomics; Pharmacy; Oncology; Books & Coffee
Views are my own 🤓
☕️📚🍂
Pharmacogenomics; Pharmacy; Oncology; Books & Coffee
Views are my own 🤓
☕️📚🍂
Reposted by Dharmisha Chauhan
"Lung cancer is a rapidly fatal disease. Speedy access to test results and effective treatments is vital," says @profrobertrintoul.bsky.social, UKLCC’s Clinical Lead.
Read our report on how we can streamline the #GenomicTesting pathway and improve outcomes for patients ow.ly/BX3X50V9wCB
Read our report on how we can streamline the #GenomicTesting pathway and improve outcomes for patients ow.ly/BX3X50V9wCB
March 4, 2025 at 1:07 PM
"Lung cancer is a rapidly fatal disease. Speedy access to test results and effective treatments is vital," says @profrobertrintoul.bsky.social, UKLCC’s Clinical Lead.
Read our report on how we can streamline the #GenomicTesting pathway and improve outcomes for patients ow.ly/BX3X50V9wCB
Read our report on how we can streamline the #GenomicTesting pathway and improve outcomes for patients ow.ly/BX3X50V9wCB
Reposted by Dharmisha Chauhan
🔥BREAKING🆙
✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit
🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC
🎙️ @bms-news.bsky.social
#LCSM @oncoalert.bsky.social
news.bms.com/news/corpora...
✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit
🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC
🎙️ @bms-news.bsky.social
#LCSM @oncoalert.bsky.social
news.bms.com/news/corpora...
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi...
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...
news.bms.com
February 19, 2025 at 2:11 PM
🔥BREAKING🆙
✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit
🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC
🎙️ @bms-news.bsky.social
#LCSM @oncoalert.bsky.social
news.bms.com/news/corpora...
✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit
🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC
🎙️ @bms-news.bsky.social
#LCSM @oncoalert.bsky.social
news.bms.com/news/corpora...
Reposted by Dharmisha Chauhan
Guidelines for managing #tarlatamab - associated toxicities in #SCLC #lcam #lcsm
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer. This review summarizes the safety profi....
acsjournals.onlinelibrary.wiley.com
February 1, 2025 at 8:22 PM
Guidelines for managing #tarlatamab - associated toxicities in #SCLC #lcam #lcsm
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Dharmisha Chauhan
In a book classed as essential knowledge, there is a brilliant chapter on pharmacogenomics authored by @dharmisha.bsky.social
& editing led by Raliat on this one.
& editing led by Raliat on this one.
January 28, 2025 at 10:20 AM
In a book classed as essential knowledge, there is a brilliant chapter on pharmacogenomics authored by @dharmisha.bsky.social
& editing led by Raliat on this one.
& editing led by Raliat on this one.